Pharmaceuticals, Biotechnology and Life Sciences
Roche presents data from a mock clinical trial study suggesting that next-generation discovery proteomics is ready for use in clinical…
Roche said Monday it got accelerated approval to Tecentriq plus chemotherapy for the treatment of adults with unresectable triple-negative breast cancer (TNBC) in people whose tumours express PD-L1, as determined by an FDA-approved test.
Roche will fully buy Spark Therapeutics at a price of $114.50 per share in an all-cash transaction, or for $4.3…
Roche on Tuesday got nod from the US Food and Drug Administration (FDA) that it’s anti-cancer combination might have the potential to provide significant improvements in the safety and effectiveness of the treatment, prevention or diagnosis of a serious disease.
Roche will wait until September 2019 for the FDA’s decision, before it can combine Tecentriq with Abraxane and carboplatin for the first-line treatment of lung cancer patients, who don’t have EGFR or ALK genomic tumour aberrations.
BioPorto and Roche agreed that BioPorto will deliver a neutrophil gelatinase-associated lipocalin (NGAL) test for use on Roche’s cobas c…
Boehringer Ingelheim today announced a collaborative agreement with Roche, focusing on the discovery and development of orally available novel Locked…
Horizon Discovery Group has entered into an agreement with Roche Diagnostics to assist in the development of immunohistochemistry (IHC) assays.
Roche has bought Vienna-based diabetes management platform mySugr for an undisclosed price, the Swiss drugmaker said on Friday, joining a growing crowd of companies expanding into app-based digital health services.
Roche’s new tablet for treating certain types of idiopathic pulmonary fibrosis (IPF) was approved by the European Commission, the Swiss drugmaker announced on Tuesday.